Rare disease

#Approvals #Rare disease #Regulatory

Biotech Recursion granted EU approval for rare disease  

Biotechnology company Recursion has been granted an Orphan Drug Designation for its potential treatment of the rare disease familial adenomatous polyposis (FAP).   FAP is a rare tumour syndrome in which hundreds or thousands of precancerous colorectal polyps grow in the body. As it stands there are… Read More

#News

#Actigen #FDA #Rare disease #Regulatory

Actigen moves closer to clinical trial for rare disease treatment  

Biotech company Actigen has moved closer to clinical trials for rare disease treatment for Hunter syndrome, following a pre-Investigational New Drug (IND) meeting with the US Food and Drug Administration (FDA).    The Cambridge-based biotech filed for a pre-IND advice meeting with the FDA to discuss the… Read More

#News

Woman with a nose bleed
#Haemophilia #Novo Nordisk #Rare disease

Novo Nordisk announces positive results for haemophilia A antibody  

Novo Nordisk has announced positive interim results for its Mim8 antibody which is being as a treatment for haemophilia A.   Novo Nordisk presented interim results from the Phase I & II FRONTIER1 dose-escalation study at International Society of Thrombosis and Haemostasis Annual Congress… Read More

#News

#Clinical trials #Diversity #Pharmaceutical #Pharmaceutical research #Rare disease

The company bringing patients to clinical trials  

DDW’s Reece Armstrong speaks to Scott Gray, President & CEO of Clincierge about its unique approach to improving the clinical trial experience for patients.   For patients participating in a clinical trial, the experience can be one of considerable hardship, both from a perspective on their health and the impact on… Read More

#Exclusive Content #Opinion

Human brain
#Biopharma #Cell and gene therapy #EMA #Rare disease

Gene therapy for rare brain disease gets nod from EMA

A gene therapy targeting a rare brain disorder has received a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). PTC Therapeutics’ one-time gene replacement therapy Upstaza was given a positive opinion for the treatment for aromatic L-amino acid decarboxylase (AADC)… Read More

#News

#Diagnostics #Genetics / genomes #Rare disease

PacBio and Children’s Mercy expand genetic research collaboration 

PacBio has expanded a research collaboration with Children’s Mercy Kansas City in an effort to improve scientists’ understanding of the genetic underpinnings of rare diseases.   The collaboration will see Children’s Mercy Kansas City use the multi-omics capabilities of PacBio’s Sequel IIe system in the study of genetic… Read More

#News

#Funding #Immunotherapy #Rare disease

Ilya Pharma closes €8.5 million to advance its clinical programmes 

Ilya Pharma, a clinical stage immunotherapy company, has closed a €8.5 million funding round, which will be used to advance the company’s portfolio of three first-in-class immunotherapies for skin and mucosal diseases.   The portfolio   The active portfolio includes ILP100-Topical for treatment surgical wounds in diabetic,… Read More

#News

#Clinical trials #Events #Life sciences #Oncology #Rare disease

BioTrinity 2022: Catalysing growth in the life sciences industry 

BioTrinity 2022 will take place April 26-27, 2022 at 155 Bishopsgate in London, UK.   The BioTrinity conference aims to catalyse growth and supports in-person engagement across the life sciences industry. The event will be attended by early-stage and emerging life sciences R&D companies, investors, large pharma,… Read More

#News

#AI / data analytics / healthtech / informatics #Drug development #Rare disease

Can real-world data transform the rare disease research landscape? 

Cytel and Pulse Infoframe have collaborated to create a solution that marks a new direction in research for rare disease. This partnership will support drug development sponsors seeking to implement real-world evidence solutions where the data generated can be used for a range of purposes, from synthetic controls and comparative effectiveness to… Read More

#News

#Biotechnology #Clinical trials #Drug design #Drug development #Rare disease #Therapeutics

Inside the rare disease centre which aims to accelerate biotech growth 

Emmes has launched a rare disease centre, Orphan Reach, to combine its health research across the public sector and biopharmaceutical industry. DDW’s Megan Thomas spoke with Thomas Ogorka, Managing Director of Orphan Reach: Emmes’ Rare Disease Center, about its potential.  MT: What will the expanded Orphan Reach centre add to what Emmes already offers?   TO: First and foremost, specialised rare… Read More

#Exclusive Content #News #Opinion

#Clinical trials #Neurology #Rare disease

First patient enrollment for ALS treatment trial 

Ferrer, a pharmaceutical company focused on neurological disorders and pulmonary vascular and interstitial lung diseases, has enrolled the first patient in its Amyotrophic Lateral Sclerosis (ALS) Deceleration with ORal Edaravone (ADORE), FNP122 Phase III clinical trial.   The trial   The trial will enrol about 300 patients across European countries and it will evaluate… Read More

#News #Trending News

#Cancer research #Clinical trials #Rare disease #Research

Accelerating research: the path forward for treating rare cancers 

Listen to this article on the DDW Podcast: RareCan is a new company based in the UK. Its aim is to accelerate research into rare cancers. However, finding suitable patients willing to take part in research and trials of new drugs is difficult, which impacts the discovery process. Professor Andy Hall, Founding Director and… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News #Opinion

#Healthcare #Public health #Rare disease

Rare disease centre to accelerate biotech growth 

Emmes has launched a rare disease centre, Orphan Reach, to combine its health research across the public sector and biopharmaceutical industry, with Orphan Reach, a UK-based CRO, acquired by Emmes in May 2021.  The expanded Orphan Reach is dedicated to the advancement of rare disease research by providing specialised clinical… Read More

#News

#Biosciences #Cancer research #Drug discovery #Rare disease

RareCan receives approval to establish BioResource at Newcastle University 

RareCan has received approval from the NHS Research Ethics Committee to establish its BioResource at Newcastle University, which will store tissue samples from rare cancer patients collected during surgery, will be accessible to scientists around the globe undertaking research into the prevention, diagnosis or treatment of rare cancers. This reduces… Read More

#News

#Funding #Rare disease #Therapeutics

Angelini Pharma and Lumira Ventures launch the ALBF

Angelini Pharma and Lumira have launched the Angelini Lumira Biosciences Fund (ALBF), which has been established to invest in early-stage companies in Canada and U.S. markets that are developing pharmaceutical therapies for central nervous system disorders (CNS) and rare diseases. The ALBF will be managed by Lumira Ventures and Angelini… Read More

#News #Start-up Zone